Recombinant foot-and-mouth disease type A virus that induces a strong adaptive immune response and overcomes interference from maternal antibodies, and foot-and-mouth disease vaccine composition containing the same

By inserting the C3d gene into FMD strains, the recombinant virus stimulates B cells to induce a strong adaptive immune response, addressing the interference of maternally transferred antibodies and enhancing vaccine efficacy in young animals.

JP2024543855AActive Publication Date: 2024-11-26REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY)
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024529412
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-17
Filing Date
2022-11-11
Publication Date
2024-11-26
Estimated Expiration
2042-11-11

AI Technical Summary

Technical Problem

Current foot-and-mouth disease (FMD) vaccines are limited by the interference caused by maternally transferred antibodies, which inhibit the formation of active immunity in young animals, necessitating delayed vaccinations and varying efficacy due to individual antibody levels.

Method used

A recombinant foot-and-mouth disease virus is developed by inserting the C3d gene (B cell epitope) into the FMD type O and A strains to directly stimulate B cells and induce a strong adaptive immune response, overcoming antibody interference.

Benefits of technology

The recombinant virus induces a robust cellular and humoral immune response, allowing for effective vaccination at earlier ages and overcoming the interference of maternally transferred antibodies, thereby enhancing vaccine efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543855000001_ABST
    Figure 2024543855000001_ABST
Patent Text Reader

Abstract

The present invention relates to a vaccine composition for FMD containing a recombinant FMD virus and an antigen isolated and purified from the virus, and provides a vaccine composition which simultaneously induces a humoral immune response through the induction of a strong cellular immune response at the early stage of vaccination, while overcoming the interference of maternal antibodies (MDA) and enabling active immunity through stimulation of B cell receptors in the presence of maternal derived antibodies, and a method for preventing or treating FMD using the composition.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an immune-enhancing recombinant FMD virus in which the C3d gene (B cell epitope) has been inserted into the FMD type A vaccine strain in order to overcome interference from maternal antibodies by inducing a strong adaptive (cellular and humoral) immune response, a method for isolating and purifying an inactivated FMD virus antigen with increased immunogenicity, and its use as a FMD vaccine composition for overcoming interference from maternal antibodies (maternally-derived antibodies, MDA). [Background technology]

[0002] Foot-and-mouth disease (FMD) vaccine requires regular and repeated vaccination of both cattle and pigs, and such vaccination transfers the antibodies induced by the mother to calves or piglets in the form of maternal antibodies via the placenta or colostrum intake, forming passive immunity. Maternal antibodies provide host protection during early FMD virus infection in calves and piglets, but their duration is short. Early vaccination of young animals with FMD vaccine causes interference by passive immunity (inducing immunological tolerance mechanism by inhibiting production of antigen-specific antibodies from plasma cells and memory B cells), thus inhibiting the efficacy of the vaccine and inhibiting the formation of active immunity. Currently, FMD vaccine vaccination programs recommend vaccination of calves and piglets after the age of 2 months, when the level of maternal antibodies decreases.

[0003] Since the level, titer and half-life of maternal antibodies vary from individual to individual, it is difficult to determine the appropriate timing for vaccination against FMD in the field. In addition, the current commercially available FMD vaccines generally have a limit in that it is difficult to overcome interference from maternal antibodies, which inhibits active immunity formation by vaccination.

[0004] Meanwhile, foot-and-mouth disease virus (FMDV) belongs to the genus Aphthovirus (family Picornaviridae) and is classified into seven serotypes: O, A, C, Asia1, SAT1, SAT2, and SAT3. Viruses that share at least 85% nucleotide identity in the FMDV genome region corresponding to the VP1 protein form a single serotype. These are generally geographically restricted and classified into topotypes. FMDV exhibits high genetic and antigenic variation, so antibodies induced by one serotype cannot neutralize other serotypes, and cross-protection is not achieved during vaccination. Nevertheless, vaccination is widely used to prevent and control the disease in countries where FMD is endemic.

[0005] B cell activation pathways are broadly divided into three: 1) T cell-dependent pathway, 2) T cell-independent type I pathway, and 3) T cell-independent type II pathway. Among these, the T cell-dependent pathway is a typical pathway in which B cells are activated via TCR / MHC, CD40L / CD40, etc., while the T cell-independent type I pathway is a pathway in which PAMP (pathogen-associated molecular pattern) stimulates pattern recognition receptors (PRRs) to directly activate B cells, and is known to be a pathway that rarely occurs in the host. Finally, the T cell-independent type II pathway is a pathway in which antigens or B cell epitopes such as C3d stimulate B cell receptors such as CD21, CD19, and CD81 to activate B cells. When maternal antibodies are present in the host, In such cases, because immune tolerance mechanisms make it difficult to present antigens to T cells, induce cellular immune responses, and activate B cells via a T cell-dependent pathway, it is necessary to directly activate B cells via a T cell-independent pathway or to continuously stimulate T cells via the induction of a strong cellular immune response.

[0006] Therefore, in the present invention, in order to overcome the interference of maternal antibodies, which has been pointed out as a major limitation of currently available FMD vaccines, we selected the active site of C3d as a candidate substance to overcome the interference of maternal antibodies by stimulating the receptor on the surface of B cells via the B cell epitope C3d, and inserted it into the O PA2 P1 backbone (VP1 site) to develop a FMDV O type FMDV vaccine strain for overcoming maternal antibody interference, an immune enhancing antigen isolated and purified from it, and a FMD vaccine composition for overcoming maternal antibody interference containing it. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Korean Patent No. 10-2234754 [Non-patent literature]

[0008] [Non-Patent Document 1] Lee, SY et al. Rapid engineering of foot-and-mouth disease vaccine and challenge viruses. J. Virol. 91, e00155-00117 (2017) [Non-Patent Document 2] Lee, MJ et al. Advanced foot-and-mouth disease vaccine platform for stimulation of simultaneous cellular and humoral immune responses. Vaccines (Basel) 8, 254 (2020) Summary of the Invention [Problem to be solved by the invention]

[0009] In light of the above background, in order to overcome the phenomenon of interference from maternal antibodies, which is a limitation of currently available FMD vaccines, the present invention aims to overcome the interference from maternal antibodies by directly stimulating receptors on the surface of B cells via the B cell epitope C3d.

[0010] Therefore, the object of the present invention is to provide an immune-enhancing recombinant FMD virus in which the C3d gene (B cell epitope) has been inserted into a FMD type A vaccine strain, in order to overcome the difficulty of inducing a FMD vaccine-mediated immune response due to interference from maternal antibodies, which has been pointed out as a limitation of currently commercially available FMD vaccines, a FMD vaccine composition containing an antigen isolated and purified from the virus, and a method for producing the recombinant FMD virus. [Means for solving the problem]

[0011] To achieve the above object, the present invention provides a FMD vaccine composition comprising a recombinant FMD virus and an antigen isolated and purified from the recombinant FMD virus.

[0012] The present invention also provides a method for producing the recombinant FMD virus, and a method for isolating and purifying an antigen from the recombinant FMD virus.

[0013] The recombinant FMD virus according to the present invention can be prepared through a recombinant plasmid into which a gene of FMD virus is inserted, and the recombinant FMD virus can be, but is not limited to, FMD virus type O or type A.

[0014] The FMD type O recombinant virus can be produced via the recombinant plasmid of SEQ ID NO:8, and the FMD type A recombinant virus can be produced via the recombinant plasmid of SEQ ID NO:11.

[0015] To prepare the recombinant foot-and-mouth disease virus, the active site of C3d (13a.a) was selected as a candidate substance to be inserted into the backbone, and the active site of C3d has sequence number 4 (the base sequence encoding this is sequence number 5).

[0016] This was inserted into the OPA2 or A22 P1 backbone (VP1 site) to produce FMDV We provide a composition for a foot-and-mouth disease vaccine that overcomes interference from maternal antibodies such as O type OPA2-C3d and FMDV type A A22-C3d.

[0017] Also provided are an immune enhancing antigen separated and purified from the antigen, and a FMD vaccine composition for overcoming maternal antibody interference, which contains the antigen.

[0018] The present invention also provides a method for preventing or treating FMD using a vaccine composition containing the recombinant FMD virus or an antigen isolated and purified from the recombinant FMD virus.

[0019] The present invention also provides a diagnostic kit for FMD or a diagnostic kit composition for FMD, which contains the recombinant FMD virus or the recombinant FMD virus antigen.

[0020] The present invention also provides a method for diagnosing FMD using the FMD diagnostic kit or FMD diagnostic kit composition.

[0021] The recombinant FMD virus of the present invention is based on type O or type A.

[0022] The O type can be, but is not limited to, O1-Manisa in one embodiment of the present invention.

[0023] Type A may be, but is not limited to, subtype A22, preferably A22 / Iraq / 24 / 64, in one embodiment of the present invention.

[0024] In the present invention, the term "plasmid" refers to a DNA preparation containing a DNA sequence operably linked to a suitable regulatory sequence capable of expressing the DNA in a suitable host. When transformed into a suitable host, the plasmid can replicate and function independently of the host genome, or in some cases can be integrated into the genome itself. Since the plasmid is currently the most commonly used form of vector, in the present specification, the terms "plasmid" and "vector" are sometimes used interchangeably.

[0025] For the purposes of the present invention, it is preferable to use a plasmid vector. A typical plasmid vector that can be used for such purposes has a structure that includes (a) an origin of replication that allows efficient replication to occur so that several hundred plasmid vectors are contained per host cell, (b) a selection marker that allows host cells transformed with the plasmid vector to be selected, and (c) a restriction enzyme cleavage site into which a foreign DNA fragment can be inserted. Even if there is no suitable restriction enzyme cleavage site, the vector and foreign DNA can be easily ligated by using a synthetic oligonucleotide adaptor or linker in a conventional manner.

[0026] The recombinant vector and recombinant FMD virus of the present invention can be produced by conventional genetic engineering and transformation methods, and an appropriate amount of the virus can be obtained by successive passage in cell culture from small amounts of the virus produced.

[0027] The cells may be derived from one or more types of cells selected from the group consisting of canine, feline, hog, bovine, cervid, giraffe, peccary, camelid, hippopotamus, equine, tapir, rhinoceros, mustelidae, leporidae, rodent and primate cells, and preferably, one or more types selected from the group consisting of goat tongue cells (ZZ-R), hamster kidney cells (BHK-21), black goat kidney cells (BGK), porcine kidney cells (IBRS-2) and bovine kidney cells (LFBK) can be used.

[0028] The foot-and-mouth disease vaccine composition of the present invention contains, as an active ingredient, the recombinant foot-and-mouth disease virus of the present invention or an antigen isolated and purified from the recombinant virus.

[0029] The recombinant FMD virus contained in the FMD vaccine composition, FMD diagnostic kit, and FMD diagnostic kit composition of the present invention may be recombinant FMD virus type O, type A, or a combination thereof.

[0030] Furthermore, the antigens isolated and purified from the recombinant FMD virus contained in the FMD vaccine composition, FMD diagnostic kit, and FMD diagnostic kit composition of the present invention may include those derived from recombinant FMD virus type O or type A, or a combination thereof.

[0031] The vaccine comprising the vaccine composition may be a live vaccine, an attenuated vaccine, or an inactivated vaccine.

[0032] The vaccine composition containing the recombinant FMD virus or an antigen isolated and purified from the recombinant virus can be administered at a dose of 1 / 640 to 1 / 10, preferably 1 / 40 to 1 / 10.

[0033] The vaccine composition may be administered to cloven-hoofed animals, such as pigs, sheep, goats, deer and wild ruminants, excluding humans.

[0034] In addition, the vaccine composition may further comprise a diluent or excipient such as a carrier, a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or the like that is generally accepted in the art.

[0035] The vaccine composition can be administered (or injected) to an individual in various forms, including subcutaneous injection, intramuscular injection, subcutaneous injection, intraperitoneal injection, nasal administration, oral administration, transdermal administration, and oral administration. Effect of the Invention

[0036] The present invention relates to a FMD vaccine composition comprising a recombinant FMD virus and an antigen isolated and purified from the virus, and provides a vaccine composition which induces a strong cellular immune response at the early stage of vaccination, thereby simultaneously inducing a humoral immune response, while overcoming MDA interference and enabling active immunity by stimulating B cell receptors in the presence of MDA. [Brief description of the drawings]

[0037] [Figure 1a] Schematic genetic diagram of the recombinant immune-enhanced foot and mouth disease type O virus according to the present invention. [Figure 1b] Schematic genetic diagram of the recombinant immune-enhanced foot-and-mouth disease type A virus according to the present invention. [Figure 2a] O. Diagram showing the immunogenicity evaluation strategy and results of antigens isolated and purified from PA2 and A22. [Figure 2b] O. Diagram showing the immunogenicity evaluation strategy and results of antigens isolated and purified from PA2 and A22. [Diagram 3] FIG. 1 shows the immunogenicity evaluation strategy and results when antigens isolated and purified from PA2 and A22 were administered in combination. [Figure 4a] FIG. 1 shows the experimental strategy (A), survival rate (B) and body weight change (C) of the recombinant FMD type O virus according to the present invention. [Figure 4b] FIG. 1 shows the experimental strategy (D), survival rate (E) and body weight change (F) of the recombinant FMD type A virus according to the present invention. [Diagram 5] FIG. 1 shows the results of inoculating mice with a vaccine containing antigens isolated and purified from the recombinant immune-enhanced foot-and-mouth disease type O and type A viruses according to the present invention, and evaluating the induction of immune responses. [Figure 6a] FIG. 1 shows a vaccination strategy for pigs containing antigens isolated and purified from recombinant immune-enhanced FMD type O and A viruses according to the present invention. [Figure 6b] This figure shows the results of evaluating early, mid and long-term immunity (induction of antibodies by SP O, A ELISA) in pigs after vaccination with a vaccine containing antigens isolated and purified from the recombinant immune-enhanced foot-and-mouth disease type O and A viruses according to the present invention. [Figure 7] FIG. 1 shows the results of evaluating early, mid and long-term immunity (induction of neutralizing antibodies) in pigs after vaccination with a vaccine containing antigens isolated and purified from the recombinant immune-enhanced foot-and-mouth disease type O and type A viruses according to the present invention. [Figure 8a] FIG. 1 shows the results of evaluating the expression of cellular immune response genes (cytokines, costimulatory molecules, etc.) following vaccination of pigs with a vaccine containing antigens isolated and purified from the recombinant immune-enhanced foot-and-mouth disease type O and type A viruses according to the present invention. [Figure 8b] FIG. 1 shows the results of evaluating the expression of cellular immune response genes (cytokines, costimulatory molecules, etc.) following vaccination of pigs with a vaccine containing antigens isolated and purified from the recombinant immune-enhanced foot-and-mouth disease type O and type A viruses according to the present invention. [Figure 8c] FIG. 1 shows the results of evaluating the expression of cellular immune response genes (cytokines, costimulatory molecules, etc.) following vaccination of pigs with a vaccine containing antigens isolated and purified from the recombinant immune-enhanced foot-and-mouth disease type O and type A viruses according to the present invention. [Figure 8d] This figure shows the results of evaluating the induction of humoral immune responses (immunoglobulin subtypes such as IgG, IgM, and IgA) mediated by vaccination in pigs with a vaccine containing antigens isolated and purified from the recombinant immune-enhancing recombinant foot-and-mouth disease type O and type A viruses of the present invention. [Figure 8e]FIG. 1 shows the results of cellular immune responses induced in mouse peritoneal exudate cells (PECs) and porcine peripheral blood mononuclear cells (PBMCs) by treatment with antigens isolated and purified from the immune-enhancing recombinant FMD type O and A viruses according to the present invention. [Figure 9] FIG. 1 shows the results of measuring the amount of antigen using a simple kit containing an antigen isolated and purified from a recombinant FMD virus according to the present invention and of differentiating it from a field strain. [Figure 10] FIG. 2 shows the results of electron microscope (TEM) observation of the antigen (146s particle) purified using the recombinant foot-and-mouth disease virus according to the present invention. [Figure 11] FIG. 1 shows the VP1 sequences of O PA2-C3d and A22-C3d of the present invention. The VP1 sequences of O PA2-C3d and A22-C3d were aligned using SnapGene at the first (Sus.1) and fourth (Sus.4) suspension cell (BHK) passages; (a) O PA-C3d nucleotide sequence, (b) A22-C3d nucleotide sequence, (c) O PA2-C3d amino acid sequence, (d) A22-C3d amino acid sequence. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0038] The present invention will be described in detail below with reference to examples and experimental examples.

[0039] However, the following examples and experimental examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples and experimental examples.

[0040] Materials and Methods 1. Preparation of Recombinant Plasmids The recombinant plasmid was produced as described by Lee et al. (Lee, SY et al. Rapid engineering of foot-and-mouth disease vaccine and challenge viruses. J. Virol. 91, e00155-00117 (2017).) The entire FMD-O1-Manisa virus genome (GenBank Accession No. AY593823.1) was amplified by PCR.

[0041] (1) Construction of recombinant plasmid for producing recombinant FMD type O virus The amplified O1-Manisa genome (SEQ ID NO: 1) was inserted into a plasmid (pBluescript SK II) to prepare pO1-Manisa (pO1 M) plasmid. The gene encoding the P1 structural protein in the prepared pO1 M was replaced with the gene encoding the structural protein of O-serotype FMDV O PA2 (SEQ ID NO: 2) (GenBank Accession No. GU384682.1) to obtain pO1 MO. The PA2 P1 (SEQ ID NO:3) plasmid was prepared.

[0042] Using the plasmid (pO1 MO PA2 P1) prepared as above, the B cell epitope sequence (C3d sequence (GGTAAGCAGCTCTACAACGTGGAGGCCACATCCTATGCC, SEQ ID NO: 4) corresponding to the amino acid residue sequence (GKQLYNVEATSYA, SEQ ID NO: 5) was inserted between the 456th and 457th base pair positions (152nd and 153rd amino acid positions, i.e., the 2025th and 2026th bases of the pO1 MO PA2 P1 sequence) of the VP1 sequence [PA2-C3d: 300ng / μL of pO1 M-A22 P1 as a PCR template, 1μL of 10pmole / μL of primer C3d F (5'-GGAGGCCACATCCTATGCCCGCGAGAGGCCCTAGGTCGC-3', SEQ ID NO: 6), 1μL of 10pmole / μL of primer C3d R(5')1μL-ACGTTGTAGAGCTGCTTACCGCGAGGGTCGCCGCTCAGCT-3', SEQ ID NO: 7) was used to prepare the target plasmid by the same self-ligating method used in the previous study. The final recombinant plasmid prepared is shown in SEQ ID NO: 8.

[0043] (2) Construction of recombinant plasmid for producing recombinant FMD type A virus The amplified O1-Manisa genome (SEQ ID NO: 1) was inserted into a plasmid (pBluescript SK II) to prepare pO-Manisa (pO1 M) plasmid. The gene encoding the structural protein in the prepared pO1 M was replaced with the gene encoding the structural protein of A serotype FMDV A22 / Iraq / 24 / 64 (GenBank Accession No. AY593764.1) (SEQ ID NO: 9) to obtain O1 The M-A22 P1 plasmid (SEQ ID NO: 10) was prepared.

[0044] Using the plasmid (O1M-A22P1) prepared as described above, the B cell epitope sequence (C3d sequence (GGTAAGCAGCTCTACAACGTGGAGGCCACATCCTATGCC, SEQ ID NO: 4) corresponding to the amino acid residue sequence (GKQLYNVEATSYA, SEQ ID NO: 5) was inserted between the 453 and 454 base pair positions (151 and 152 amino acid positions, i.e., 2025th and 2026th bases of the pO1MOPA2P1 sequence) of the VP1 sequence. Then, O1 M-A22 P1 300ng / μL, primer Cd3 F (5'-GGAGGCCACATCCTATGCCCGCGAGAGGCCCTAGGTCGC-3', SEQ ID NO: 6) 1μL at 10pmole / μL, and primer C3d R (5'-ACGTTGTAGAGCTGCTTACCGCGAGGGTCGCCGCTCAGCT-3', SEQ ID NO: 7) 1μL at 10pmole / μL were used to prepare the target plasmid by the same self-ligating method used in the previous study. The final recombinant plasmid produced is shown in SEQ ID NO:11.

[0045] Figure 1a and Figure 1b show schematic diagrams of the final plasmids for OPA2-C3d and A22-C3d, respectively.

[0046] The PCR conditions were as follows: 10 μL of 5× Phusion HF buffer (Thermo Scientific, Waltham, MA, USA), 1 μL of 10 mM dNTPs (Invitrogen, Carlsbad, CA, USA), 1 μL of 2 U / μL Phusion DNA polymerase (Thermo Scientific) and 35 μL of sterile distilled water were amplified at 98° C. for 30 s, 98° C. for 10 s, 65° C. for 20 s, 72° C. for 2 min and 30 s for 25 cycles, with a final cycle of 72° C. for 10 min. Next, 1 μL of DpnI (Enzynomics, Daejeon, Korea) was added to the 25 μL PCR product and reacted in a 37° C. incubator for 1 h. Then, 35 μL of sterile distilled water, 5 μL of Ligation High (Toyobo, Osaka, Japan) and 1 μL of 5 U / μL T4 polynucleotide kinase (Toyobo, Osaka, Japan) were added to 4 μL of the DpnI-treated product. The mixture was allowed to ligate in a water bath at 16° C. for 1 hour.

[0047] After ligation, the plasmid was transformed into 100 μL of DH5α cells (Yeast Biotech, Taipei, Taiwan) according to the manufacturer's protocol. The transformed cells were spread onto ampicillin-containing agar plates and grown overnight at 37°C.

[0048] Colonies were selected from the plate with pipette tips and mixed with 18 μL of sterile distilled water, 1 μL of 10 pmol forward universal primer VP1 (5'-AGNGCNGGNAARTTTGA-3') (SEQ ID NO: 12) and 1 μL of 10 pmol / μL reverse universal primer. Primer VP1 (5'-CATGTCNTCCATCTGGTT-3') (SEQ ID NO: 13) was placed in a colony PCR tube and PCR amplification was performed for a total of 25 cycles at 94°C for 5 min, 94°C for 30 s, 55°C for 30 s, 72°C for 1 min, and the final cycle at 72°C for 5 min. In the universal primer, N can represent any nucleotide. 5 μL of PCR sample was mixed with 1 μL of 6× loading buffer (DYNE BIO, Gyeonggi-do, Korea) and then loaded onto an agarose gel. Then, 5 μL of 100 bp marker (DYNE BIO) was also loaded onto the gel. After electrophoresis at 100V for 30 min, the bands were evaluated with Gel Doc. After band evaluation, 5 μL of PCR product was mixed with 2 μL of ExoSAP (Thermo Scientific) and amplified by PCR at 37°C for 15 min and 85°C for 15 min. Insertion of the epitope into VP1 was confirmed by total DNA sequencing. After confirming the base sequence, the colony was placed in 200 mL of LB medium containing ampicillin and cultured overnight at 37°C with shaking. Plasmids were prepared using Midi prep (MACHEREYNAGEL, Duren, Germany).

[0049] 2. Preparation of Immuno-enhancing Recombinant FMD Virus The recombinant FMD virus was prepared by transfecting BHKT7-9 (a cell line expressing T7 RNA polymerase) with the recombinant plasmid prepared above using Lipofectamine 3000 Reagent (Invitrogen, Carlsbad, CA, USA) and then culturing the cells for 2 to 3 days and harvesting them. The prepared virus was then passaged into fetal goat tongue (ZZ-R) cells or baby hamster kidney-21 (BHK-21) cells for virus propagation.

[0050] 3. Purification of antigens (inactivated viruses) from recombinant FMD type O and type A viruses that display C3d-epitopes on their surface Purified antigens were produced from BHK-21 cells infected with recombinant immunostimulatory FMDV O PA2-C3d and A22-C3d, which were constructed by reverse genetics against the rapid phenotype of P1 (referenced sequences) according to the method described by Lee et al. (Non-Patent Document 2) with modifications.

[0051] For viral infection, the culture medium was replaced with serum-free Dulbecco's Modified Eagle's medium (DMEM; HyClone, Logan, UT, USA) and the cells were incubated at 37 °C for 24 h at 5% CO 2The cells were incubated at 37°C for 1 h to inoculate the virus. Extracellular virus was then removed. 24 h after infection, the virus was inactivated by treating twice with 0.003 N binary ethyleneimine for 24 h in a shaking incubator, and then concentrated with polyethylene glycol (PEG) 6000 (Sigma-Aldrich, St. Louis, MO, USA). The virus concentrate was layered on a 15%-45% sucrose density gradient and centrifuged. After ultracentrifugation, 1 mL fractions were collected by puncturing the bottom of the centrifuge tube. The presence of FMDV particles in each fraction sample was confirmed by optical density using a lateral flow device (BioSign FMDV Ag; Princeton BioMeditech, Princeton, NJ, USA). Prior to use in the field experiments, the pre-PEG-treated supernatant was passed through ZZ-R and BHK-21 cells at least twice to confirm the absence of cytopathic effect (CPE), thereby confirming the absence of viable virus in the supernatant.

[0052] 4. Confirmation of structural and nonstructural proteins using purified antigens and examination of 146S particles using TEM The structural proteins (SPs) of purified antigens expressed in cells infected with immune-enhancing recombinant FMDV O PA2-C3d and A22-C3d were identified with a Rapid Antigen Kit (PBM Kit, PBM Co Ltd., Princeton, NJ, USA), which showed banding for SPs. There was no banding for FMDV nonstructural proteins (NSPs). The viral particles (146S) were characterized by transmission electron microscope (TEM) imaging. In addition, since sequence changes are frequent when recombinant viruses are passaged, in order to prove that the sequence did not change during the first and fourth passages, we confirmed whether the FMDV with a specific epitope of "C3d" maintained the genetic stability of the virus even after passage in cells, and finally confirmed that there was no sequence change up to the fourth passage (Figure 11).

[0053] 5. Evaluation of immunogenicity in experimental animals (mice) of immune-enhancing FMD vaccine strains, OPA2-C3d and A22-C3d, for overcoming maternal antibody interference (1) Mice Mouse experiments were performed according to the method described by Lee et al. (Non-Patent Document 2). Age- and sex-matched wild-type C57BL / 6 mice (female, 6-7 weeks old) were purchased from KOSA BIO Inc. (Gyeonggi, Korea). All mice were housed in microisolator cages with free access to food and water in the specific pathogen-free (SPF) biosafety level 3 (ABSL3) animal facility of the Animal and Plant Quarantine Agency. All animals were allowed to acclimate for at least 1 week before use in experiments. The breeding room was set to a 12-hour light-dark cycle, a temperature of approximately 22 °C, and a relative humidity of approximately 50%. The study was performed in accordance with the institutional guidelines and approval of the Animal Experiment Ethics Committee of the Animal and Plant Quarantine Agency (certification number IACUC-2021-584).

[0054] (2) Vaccination and administration of FMDV to mice To verify the immunogenicity and short-term immune induction effect of antigens isolated and purified from highly immunogenic FMDV O PA2-C3d and A22-C3d, and to confirm their potential as master seed viruses (MSVs) for the development of a foot-and-mouth disease vaccine, To this end, animal experiments were carried out as follows.

[0055] The composition of the vaccine used in the experiment was as follows: O PA2-C3d and A22-C3d (15 μg / dose / mL, 1 / 10 to 1 / 640 dose for pigs), ISA 206 (Seppic, Paris, France, 50%, w / w), 10% Al(OH). 3 and 15 μg / mouse Quil-A (InvivoGen, San Diego, CA, USA). Mice were injected intramuscularly (IM) into the thigh muscle (0 days post-vaccination (dpv)) with 100 LD 50 ME-SA topotype or 100 LD 50Mice were administered intraperitoneal (IP) injection of 100-fold increased IgG antibody (IgG1, IgG2a / Malay / 97, SEA topotype) at 7 dpv. Mice in the negative control group received an equal volume of phosphate-buffered saline (PBS, pH 7.0) via the same route. Survival and body weight changes were monitored up to 7 days post-challenge (dpc) to assess short-term immunogenicity.

[0056] As a preliminary experiment for experiments in target animals (pigs), PD was performed to confirm the immunogenicity of a bivalent test vaccine containing OPA2-C3d antigen + A22-C3d antigen. 50 The O. erythropoietin was used as the backbone for the immune-boosting vaccine strain. The test vaccine groups containing PA2 antigen + A22 antigen were compared together. The composition of the vaccine used in the experiment was as follows: O PA2-C3d antigen + A22-C3d antigen (15μg + 15μg / dose / ml, 1 / 10 to 1 / 640 dose) or O PA2 antigen + A22 antigen (15μg + 15μg / dose / ml, 1 / 10 to 1 / 640 dose), ISA 206 (50%, w / w), 10% Al(OH) 3 , 15 μg Quil-A / mouse. For the negative control group, the same volume of PBS was administered via the same route.

[0057] Mice were vaccinated IM at 0 dpv and then immunized with FMDV (100 LD 50 , O / VET / 2013, ME-SA topotype or 100 LD 50 A / Malay / 97, SEA topotype) was administered intraperitoneally to mice, and survival rates and changes in body weight were monitored up to 7 days post challenge (dpc).

[0058] 6. Evaluation of immunogenicity in target animals (pigs) of immune-enhancing FMD vaccine strains, OPA2-C3d and A22-C3d, for overcoming maternal antibody interference (1) Pig Pigs (8-9 weeks old, total n=32) were analyzed for antibody titers (PI value: 50% standard) and VN titers (1.6 Log 10 Patients were screened according to the following criteria and divided into MDA(+) and MDA(-) groups (n=16 per group).

[0059] The pigs in each group, corresponding to the MDA(+) and MDA(-) groups, were randomly divided into three groups (n=4 or 6 / group): NC (negative control group), O PA2+A22 (positive control group, PC) treatment, and O PA2-C3d+A22-C3d treatment group.

[0060] The animals were isolated in a closed isolation room (ABSL3) during the experimental period. After arriving at the ABSL, all animals were kept in cages with free access to food, drink and water (ad libitum) and were used in the experiments after at least one week of adaptation. The breeding room was set to a 12-hour light-dark cycle, a temperature of approximately 22°C, and a relative humidity of approximately 50%. The present invention was conducted in accordance with the institutional guidelines approved by the Animal Experiment Ethics Committee of the Agriculture, Forestry and Fisheries Quarantine Agency (certification number IACUC-2021-584).

[0061] (2) Induction of immune responses by vaccination and sampling Immuno-enhancing FMD antibody was developed to overcome maternal antibody interference in pigs, the target animal. To evaluate the immunogenicity of antigens isolated and purified from the vaccine strains O PA2-C3d and A22-C3d, and to observe the effect of inducing adaptive immune responses and overcoming the effect of avoiding interference from maternal antibodies, experiments were conducted using maternal antibody positive (MDA(+), FMD-seropositive) and negative (MDA(-), FMD-seronegative) field pigs. The composition of the vaccine was as follows: 15 μg of O PA2 antigen + 15 μg of A22 antigen (positive control group, PC group) or 15 μg of O PA2-C3d antigen + 15 μg of A22-C3d antigen (experimental group, experimental group), ISA 206 (50%, w / w), 10% Al(OH) 3 The negative control group (NC group) was administered the same volume of PBS via the same route.

[0062] Pigs aged 8-9 weeks were screened for maternal antibody positive and negative animals and divided into two categories, MDA(+) group (n=16) and MDA(-) group (n=16). Individuals from MDA(+) and MDA(-) groups were divided into three groups, NC group (PBS administered group, n=4 / group), PC group (O PA2+A22 administered group, n=6 / group), and experimental group (O PA2-C3d+A22-C3d administered group, n=6 / group), and 1 mL of vaccine was administered via IM route twice at 28-day intervals (0 dpv, 28 dpv). Blood samples of vaccinated pigs were collected at 0, 7, 14, 28, 42, 56, 70, and 84 dpv for serological analysis such as SP O, A ELISA, and VN titer confirmation. In the case of SP O, A ELISA, taking into consideration the antibody positivity rate due to the characteristics of the antigen, PrioCHECK for FMDV O type and A type was used. TMWe also isolated peripheral blood mononuclear cells (PBMCs) from blood samples collected during all sampling schedules and analyzed the changes in gene expression related to the test vaccine-mediated cellular and humoral immune responses.

[0063] (3) Serological analysis PrioCHECK to detect SP antibodies in serum TM FMDV type O or FMDV type A (Prionics AG, Switzerland) and VDPro® FMDV type O or FMDV type A (Median Diagnostics, Gangwon-do, Korea) were used. The absorbance of the ELISA plate was converted into a percent inhibition (PI) value. The PI value was calculated using the PrioCHECK TM Animals were considered seropositive if they were ≥ 50% for the FMDV kit or ≥ 40% for the VDPro® FMDV kit.

[0064] The virus neutralization test (VNT) was performed according to the World Organization for Animal Health (OIE) manual. Serum was heat inactivated at 56 °C for 30 min in a water bath. The cell density was adjusted to form a 70% monolayer, and two-fold serial dilutions (1:8 to 1:1024) of serum samples were prepared. The diluted serum samples were then transferred to a 100-tissue culture infectious dose (TCID 50 The wells were incubated with 0.5 mL of homologous virus per well for 1 h at 37°C. After 1 h, LF-BK (bovine kidney) cell suspension was added to all wells. After 2–3 days, CPE was assessed to determine the titer, which was determined by incubating the wells with 100 TCID of virus. 50 Log of reciprocal antibody dilution required to neutralize 10 Values ​​were calculated as: FMDV O / PA2 and FMDV A22 / IRAQ were used for the VNT.

[0065] (4)PECs isolation and cell culture Naive mice were CO 2 The animals were anesthetized with Ca and sacrificed. 2+ / Mg2+ The peritoneal cavity was lavaged with 5 mL of chilled Hank's balanced salt solution (HBSS, Gibco, Waltham, MA, USA) buffer free of phenol red. The peritoneal lavage fluid was centrifuged at 300 × g for 10 min at 4 °C. The pelleted PECs were resuspended and purified using Bio-Ray. d Counting was performed using a TC20 automated cell counter (Bio-Rad). All cells were freshly isolated before use. No cryopreserved cells were used in any experiments. Purified PECs were then cultured in complete medium composed of Roswell Park Memorial Institute (RPMI) 1640 (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (HyClone), 3 mM L-glutamine (Sigma-Aldrich), 10 mM HEPES (Sigma-Aldrich), 100 U / mL penicillin / streptomycin (Sigma-Aldrich), and 0.05 mM 2-β-mercaptoethanol (Sigma-Aldrich). Culture was performed at 37°C and 5% CO 2 It was held.

[0066] (5)PBMCs isolation and cell culture Porcine PBMCs were isolated from whole blood of pigs vaccinated at the specific time points (n=4 or 6 / group) described above according to the method described by Lee et al. (Non-Patent Document 2). Whole blood (20 mL / animal) was collected independently from BD Vaccutainer heparin tubes (BD, Becton, Dickinson and Company, Franklin Lakes, NJ, USA). PBMCs were isolated using Ficoll-Paque TM PBMCs were isolated using PLUS (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) gradient centrifugation. Residual red blood cells were lysed by treatment with ammonium chloride-potassium (ACK) lysis buffer (Gibco, Carlsbad, CA, USA). PBMCs were then diluted with Ca 2+ and Mg 2+The PBMCs were suspended in Dulbecco's PBS (Gibco) without PBS, supplemented with 2% fetal bovine serum (FBS) (Gibco), and counted using a volumetric flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany). All cells were freshly isolated before use. No cryopreserved cells were used in any experiment. Purified PBMCs were then resuspended in RPMI1640 (Gibco) medium supplemented with 10% FBS (HyClone, Logan, UT, USA), 3 mM L-glutamine (Sigma-Aldrich, St. Louis, MO, USA), and 100 U / mL penicillin-streptomycin (Sigma-Aldrich).

[0067] PBMCs 2+ / Mg 2+ The cells were suspended in DPBS (Gibco) without PBS and counted using a Bio-Rad TC20 automated cell counter (Bio-Rad). All cells were freshly isolated before use, and no cryopreserved cells were used in any experiment. Purified PBMCs were then resuspended in RPMI-1640 (Gibco) medium supplemented with 10% FBS (Gibco), 3 mM L-glutamine (Sigma-Aldrich), 10 mM HEPES (Sigma-Aldrich), and 100 U / mL penicillin-streptomycin (Sigma-Aldrich). Incubation was performed at 37°C and 5% CO 2 It was held.

[0068] (6) In vitro antigen-induced IFNγ ELISpot analysis of PEC and PBMC O PA2-C3d and A22-C3d antigen-mediated IFNγ secretion was analyzed using commercial ELISpot assay kits (catalog numbers EL485 and EL985 for mouse and pig, R&D Systems, Minneapolis, MN, USA) according to the manufacturer's guidelines. Isolated murine PECs or pig PBMCs (5 × 10 5The cells / well were cultured in 96-well PVDF-supported microplates containing a monoclonal capture antibody specific for mouse or porcine IFNγ and incubated with inactivated FMDV (O PA2, O PA2-C3d, A22, A22-C3d) antigens at 4 μg / mL (final concentration) at 37°C in 5% CO. 2 The cells were stimulated for 18 hours in a humidified incubator at 37 °C. PBS and 5 μg / mL phorbol miltiorrhizolium were used as negative and positive controls, respectively. Propylene glycol methacrylate (PMA, Sigma-Aldrich) was used. Plates were washed with washing buffer and incubated with biotinylated anti-mouse IFNγ antibody (1:119) or anti-pig antibody (1:119) overnight at 4°C, followed by incubation with AP-conjugated streptavidin (1:119) for 2 h at RT. Plates were washed, developed with 5-bromo-4-chloro-3'indolylphosphate p-toluidine salt (BCIP) / nitroblue tetrazolium chloride (NBT) and counted using an ImmunoSpot ELISpot reader (AID iSpot reader system; Autoimmune Diagnostika GmbH, Strassberg, Germany). Results were expressed in spot-forming units (SFU).

[0069] (7) RNA isolation, cDNA synthesis, and quantitative real-time PCR Total RNA was extracted from purified porcine PBMCs using TRIzol reagent (Invitrogen) and RNeasy Mini Kits (QIAGEN, Valencia, CA, USA). cDNA was prepared by reverse transcription using the GoScript reverse transcription system (Promega, Madison, WI, USA) according to the manufacturer's guidelines. Synthesized cDNA was amplified by quantitative real-time PCR (qRT-PCR) on a Bio-Rad iCycler using iQ SYBR Green Supermix (BioRad, Hercules, CA, USA).

[0070] Gene expression levels were normalized to hprt levels and presented as relative ratios compared to the control group. The primers used in this invention are listed in Table 1.

[0071] Primer sequence table for qRT-PCR [Table 1]

[0072] 7. Statistics All quantitative data were expressed as mean ± standard error of the mean (SEM) unless otherwise stated. Statistical significance between groups was evaluated using two-way ANOVA followed by Tukey post-hoc test, or one-way ANOVA followed by Tukey post-hoc test. *p<0.05; **p<0.01; ***p<0.001; and ****p<0.0001. Parametric tests were used to compare different groups. Survival curves were generated using the Kaplan-Meier method, and differences were analyzed using the log-rank sum test. GraphPad Prism 9.1.2 (GraphPad, San Diego, CA, USA) software and IBM SPSS software (IBM Corp., Armonk, NY, USA) were used for all statistical analyses.

[0073] <Example> Construction of immune-enhancing FMD vaccine strain to overcome maternal antibody interference, production and purification of inactivated antigen using OPA2-C3d and A22-C3d To develop a FMD vaccine strain that overcomes maternal antibody interference, reverse genetics was used. The P1 backbones of the O1 Manisa-O PA2 (O1 MO PA2) and O1 Manisa-A22 / Iraq / 24 / 64 (O1 M-A22) strains, which had already been developed using the CDC genetics, were used. In the case of type O, O PA2 was determined to be the most powerful candidate vaccine strain based on the vaccine matching rate against the surrounding outbreak situation, the proliferation of the virus in suspended cells, and especially the antigen-mediated immunogenicity in experimental animals (mice) and target animals (pigs). In the case of type A, A22 was classified as the most suitable vaccine strain, even though the matching rate generally showed a low trend in the global outbreak situation.

[0074] In the present invention, the strategy for constructing FMD vaccine strains for overcoming maternal antibody interference of FMDV type O and type A by inserting the active site of C3d, which is a B cell epitope, into the O PA2 and A22 P1 backbones is shown in Figures 1a and 1b. The detailed method is described in Materials and Methods.

[0075] <Experimental Example 1> Evaluation of immunogenicity in mice of FMD vaccines containing immune-enhancing FMD vaccine strains, OPA2-C3d and A22-C3d antigens to overcome maternal antibody interference To confirm the immunogenicity in mice of O PA2-C3d and A22-C3d, which are antigens isolated and purified from O PA2 and A22, into which the B cell epitope C3d has been inserted for B cell activation, and to evaluate their potential as a FMD vaccine master seed virus (MSV), and their protective effect against FMDV infection, O PA2-C3d and A22-C3d were used in experiments using the strategies shown in Figure 4a (A) and Figure 4b (D), respectively. O PA2 and A22 were used in experiments using the strategies shown in Figure 2a (A) and Figure 2b (D). The composition of the vaccine used in the experiments was as follows: O PA2-C3d or A22-C3d antigen, O PA2 or A22 antigen (15 μg / dose / mL, 1 / 10 to 1 / 640 dose), ISA206 (50%, w / w), 10% Al(OH). 3 , 15 μg Quil-A / mouse.

[0076] Mice were vaccinated 0 days post vaccination (IM) and then 7 days post vaccination (dpv) with FMDV type O (100 LD 50 , O / VET / 2013, ME-SA topotype) or FMDV type A (100LD 50 , A / Malay / 97, SEA topotype) were intraperitoneally administered to mice, and survival rates (Figure 4a (B) and (C)) and body weight changes (Figure 4b (E) and (F)) were monitored up to 7 days after administration (dpc).

[0077] The results showed that the test vaccine containing the OPA2-C3d antigen caused 97.01 PD 50 (Log 4 ) and the survival rate was 100% at 1 / 10, 1 / 40, and 1 / 160 doses, and 80% at 1 / 640 doses. The weight loss was also 1 / 10, 1 / 40, and 1 / 640 doses. In addition, when the test vaccine using the antigen isolated and purified from A22-C3d was administered to mice, the vaccine produced 73.52 PD 50 (Log 4 ) and the survival rate was 100% at 1 / 10, 1 / 40, and 1 / 160 doses, and 60% at 1 / 640 doses. There was almost no change in body weight at 1 / 10, 1 / 40, and 1 / 160 doses (Figure 4b (E) and (F)).

[0078] However, the vaccine containing the O PA2 antigen had a PD of 55.72 50 (log 4 ) (FIG. 2a (B)). The body weight change of O-PA2 was reduced to a lower level compared to O-PA2-C3d (FIG. 2a (C)).

[0079] The vaccine containing the A22-C3d antigen showed 100% survival rate for the 1 / 10, 1 / 40 and 1 / 160 doses, with a PD of 73.52. 50 (Log4 ) with a 60% survival rate for the 1 / 640 dose. There was no change in body weight for the 1 / 10, 1 / 40 and 1 / 160 doses.

[0080] However, the vaccine containing the A22 antigen had a PD of 6.06 50 (Log 4 ) (FIG. 2B (E)). The body weight change of A22 was reduced to a lower level compared to A22-C3d (FIG. 2B (F)).

[0081] A PD50 study was performed in pigs to confirm the immunogenicity of the bivalent investigational vaccine (containing O PA2-C3d+A22-C3d antigens, co-administration of O PA2-C3d and A22-C3d). The results were compared with those of the group that received the investigational vaccine (containing O PA2+A22 antigens, co-administration of O PA2 and A22) used as the backbone of the immune-enhancing vaccine strain (Figure 5 and Figure 3).

[0082] In the experimental strategy shown in Figure 5(A) and Figure 3(A), vaccination in mice was administered IM at 0 dpv with 100 LD of FMDV (O / VET / 2013). 50 , ME-SA topotype or A / Malay / 97 100 LD 50 Mice (SEA topotype) were challenged IP on 7 dpv. Survival and body weight changes were monitored from 0 dpc (0 days post challenge) to 7 dpc.

[0083] The bivalent vaccine containing O PA2+A22 antigens suppressed PD1 expression in mice when challenged with O / VET / 2013 and A / Malay / 97, respectively. 50 (Log 4 ) values ​​were 5.66 and 4 (Figures 3B and 3D).

[0084] A bivalent vaccine containing O PA2-C3d + A22-C3d antigens was administered with O / VET / 2013 and A / Malay / 97, respectively, resulting in PD 50 (Log 4) value is 90.5 and >128 PD 50 (Log 4 ) and exhibited high immunogenicity (Figure 5(B) and Figure 5(D)).

[0085] <Experimental Example 2> Evaluation of the immune effect (early, mid and long term) in target animals (pigs) of FMD vaccines containing immune-enhancing FMD vaccine strains, OPA2-C3d and A22-C3d antigens to overcome maternal antibody interference To evaluate the immunogenicity of antigens isolated and purified from the immune-enhancing FMD vaccine strains OPA2-C3d and A22-C3d, which were produced to overcome maternal antibody interference in pigs as the target animals, and to observe the effect of inducing adaptive immune responses and the effect of overcoming maternal antibody interference, experiments were conducted using maternal antibody-positive (MDA(+), FMD-seropositive) and -negative (MDA(-), FMD-seronegative) field pigs (Figure 6a).

[0086] As a result, when the test vaccine containing O PA2-C3d + A22-C3d antigen was administered to the pigs in the MDA(+) group to confirm the effect of overcoming maternal antibody interference, the antibody titer by SP O ELISA was significantly increased from 14 dpv compared to the PC group vaccinated with the test vaccine containing O PA2 + A22 antigen (p<0.001, PrioCheck TM Kit, VDPro® Kit), p<0.05 at 28 dpv (PrioCheck TM The significance of the difference was p<0.0001 (VDPro® kit) and p<0.01 (VDPro® kit) (Figure 6b (A) and (B)). In particular, after boosting with the second test vaccine on 28 dpv, the antibody titer was very high in the experimental group, whereas the NC group showed a tendency for maternal antibodies to continuously decrease. The antibody titers between the two groups at 56, 70, and 84 dpv showed differences at the p<0.0001 or p<0.001 level. In addition, in the case of the SP A ELISA in the MDA(+) group, it was found that the antibody titer of the experimental group at 42 dpv was higher than that of the PC group (p<0.001, PrioCheck TMSignificant differences between the experimental and NC groups at 56, 70, and 84 dpv were observed at the levels of p<0.5, p<0.0001, p<0.001 (PrioCheck® kit), and p<0.0001 (VDPro® kit), respectively (Figure 6b (C) and (D)).

[0087] On the other hand, in order to confirm the immunogenicity of the test vaccine containing the O PA2-C3d + A22-C3d antigen in the target animals (pigs) and the induction of early, mid and long-term immunity, the antibody titer by SP O ELISA was measured at 7 dpv (PrioCheck) when the vaccine was administered to the MDA(-) group. TM The antibody titers in the MDA(-) group by SP A ELISA for each group were also significantly higher than those in the NC group at 7 dpv (PrioCheck kit) and 14 dpv (VDPro® kit) at a level of p<0.05, and showed significance compared to the NC group from 28 dpv to 84 dpv (p<0.0001) (Figure 6b (E) and (F)). As with the results of the SP O ELISA, the antibody titers in the MDA(-) group by SP A ELISA for each group were also significantly higher than those in the NC group at 7 dpv (PrioCheck kit) and 14 dpv (VDPro® kit). TM The experimental group showed a significant difference at 14 dpv (VDPro® kit) and 14 dpv (VDPro® kit) (p<0.01, p<0.05), and the antibody titers were higher in the experimental group than in the NC group from 28 to 84 dpv (p<0.0001, p<0.001, p<0.01, p<0.05). The antibody titers in the experimental group were also consistently higher than those in the PC group. Significance between the two groups was observed at 14 and 84 dpv at p<0.01 and p<0.05 (VDPro® kit) (Figure 6b (G) and (H)).

[0088] Before vaccination (0 dpv), the neutralizing antibody titers against O1 Campos, A2001 Argentina, and A24 Cruzeiro in the MDA(+) / MDA(-) groups are shown in Figure 7A. In the MDA(+) group, all were >1.6 Log 10 The levels were <1.2 Log in the MDA(-) group. 10The neutralizing antibody titers were confirmed using homologous viruses against O PA2 and A22, the backbone viruses used as antigens in the PC group (Figures 7(B) and (C)). In the MDA(+) group, the antibody titers by SP O and A ELISA were high at 0 dpv, but the neutralizing antibody titers against O PA2 and A22 were low and below the protective level (Figure 7(B)). This is considered to be because the mothers of piglets with high maternal antibodies (MDA(+)) were vaccinated with Company B's vaccine, resulting in low antibody titers against heterologous viruses such as O PA2 and A22.

[0089] In the MDA(-) group, the neutralizing antibody titer against O PA2 (Figure 7(C)) was significantly higher than the NC and PC groups in the experimental group administered the test vaccine containing O PA2-C3d+A22-C3d antigen from 7 dpv (p<0.05), and continued to increase until 14 and 28 dpv (p<0.01, p<0.05). After boosting at 28 dpv, the titer increased more than the NC group from 42 to 84 dpv (p<0.0001, p<0.001, p<0.01, p<0.05). After boosting, the neutralizing antibody titer was also higher in the experimental group than in the PC group, but the significance between the two groups was observed at 42 and 84 dpv. (p<0.001, p<0.01).

[0090] The neutralizing antibody titers against A22 in the MDA(+) and MDA(-) groups (Figures 7(D) and (E)) were higher in the experimental group than in the NC and PC groups at 28 dpv (p<0.01), and after boosting, increased to higher levels than in the NC group from 42 to 84 dpv (p<0.0001, p<0.001). The difference between the experimental group and the PC group was significant from 42 to 84 dpv (p<0.0001, p<0.001).

[0091] <Experimental Example 3> Evaluation of induction of cellular immune response in pigs by FMD vaccine containing immune-enhancing FMD vaccine strains, OPA2-C3d and A22-C3d antigens to overcome maternal antibody interference 3-1. As shown in Figure 6a, after inoculating the test vaccine containing OPA2-C3d and A22-C3d antigens into the target animals, pigs, PBMCs were isolated from whole blood at each sampling time, and changes in the expression of genes such as cytokines (IFNα, IFNβ, IFNγ, IL-1β, IL-17A, IL-23p19, IL-23R, IL-2, IL-10, TGFβ, IL-4, IL-6) and costimulatory molecules (CD40, CD80, CD86, MHC class I, MHC class II, CD21, CD28, CTLA4, ICOS, AHNAK) related to the induction of cellular immune responses were observed via qRT-PCR (Figures 8a to 8c).

[0092] As a result, the expression of proinflammatory cytokine genes was observed to be very high overall. In particular, the expression of type I IFNα and IFNβ was significantly increased in the experimental group compared to the NC group at 7 dpv in the MDA(+) / MDA(-) condition (p<0.0001, p<0.001). Meanwhile, the difference between the PC group and the NC group was that in the case of IFNα, the PC group was higher than the NC group in both the MDA(+) / MDA(-) condition (p<0.01), but in the case of IFNβ, it was significantly increased compared to the NC group only in the MDA(+) condition (p<0.01). The expression level of IFNγ was somewhat lower than that of IFNα and IFNβ, but was significantly higher in the experimental group compared to the NC group in both the MDA(+) / MDA(-) condition (p<0.05).

[0093] IL-1β was significantly higher in the experimental group than in the NC group under MDA(+) / MDA(-) conditions (p<0.0001, p<0.001), and in particular, the experimental group showed a significant difference at the p<0.0001 level compared to the PC group. IL-17A was significantly higher in the experimental group than in the NC group under MDA(+) / MDA(-) conditions (p<0.0001, p<0.01), and significance was observed between the PC group and the NC group in the MDA(+) condition (p<0.01). IL-23p19 expression was also significantly higher in the experimental group than in the NC group under MDA(+) / MDA(-) conditions (p<0.01, p<0.001), and in particular, a significant difference was observed between the experimental group and the PC group under the MDA(-) condition (p<0.05). The expression of IL-23R was also very high, as were the other cytokines, and showed a significant difference between the experimental group and the NC group in both MDA(+) and MDA(-) conditions (p<0.05). In the case of IL-4 and IL-6, the expression levels were higher in the MDA(+) condition than in the MDA(-) condition, with significance between the experimental group and the NC group in the MDA(+) condition (p<0.01), and significance between the PC group and the NC group for IL-4 and IL-6 (p<0.01 and p<0.01, respectively). In the MDA(-) condition, a significant difference was observed between the experimental group and the NC group in IL-4 (p<0.05). On the other hand, in the case of the anti-inflammatory cytokine IL-10, the experimental group showed higher expression than the NC group in the MDA(+) and MDA(-) conditions (p<0.05). In the case of IL-2 and TGFβ, the expression levels were higher in the experimental group > PC group > NC group, but no significance was observed between the groups.

[0094] The expression levels of costimulatory molecules were generally somewhat lower than those of cytokines, but the expression levels were significantly higher in the experimental group than in the PC or NC groups. The expression of D21, CD28, CTLA4, and ICOS showed a tendency to increase when vaccinated under MDA(-) conditions compared to MDA(+) conditions, and showed significance in the comparison between the experimental group and the NC group under MDA(+) / MDA(-) conditions (p<0.0001, p<0.001, p<0.01, p<0.05), and the significance between the PC group and the NC group was observed at the level of p<0.01 and p<0.01 for the expression of the remaining genes except ICOS. Of these, CD80, CD21, and CD28 showed very high gene expression changes due to the administration of the test vaccine. In the case of ICOS, the significance between the experimental group and the PC group was p<0.01 under MDA(+) conditions and p<0.0001 under MDA(-) conditions, and the strain with C3d inserted showed higher gene expression than the backbone strain.

[0095] For CD86 and AHNAK, significance was observed between the experimental and NC groups under MDA(-) conditions (p<0.0001, p<0.001), and in particular, significant significance was observed between the experimental and PC groups (p<0.0001) for CD86. On the other hand, gene expression of MHC class I was decreased under MDA(-) conditions compared to MDA(+), and no significance was observed between the groups for CD40 and MHC class II.

[0096] 3-2. The humoral immune responses mediated by the immune-enhanced FMD virus types O and A (O PA2-C3d and A22-C3d) according to the present invention, measured in pigs by immunoglobulin subtypes such as IgG, IgM and IgA, are as follows:

[0097] Pigs (8-9 weeks old) that were FMD antibody-positive (MDA(+), n=16) or FMD antibody-negative (MDA(-), n=16) were divided into three groups: a negative control group (NC, n=4 / group), a positive control group (PC, n=6 / group), and an experimental group (Exp., n=6 / group).

[0098] The experimental group received O PA2-C3d+A22-C3d antigen and ISA 206 (oil-based emulsion, 50%, w / w), 10% Al(OH) 3The positive control group (PC) received the test vaccine containing 15 μg (single dose for cattle and pigs) of O PA2+A22 antigen and ISA 206 (oil-based emulsion, 50%, w / w), 10% Al(OH) 3 , and 15 μg with 150 μg Quil-A (single dose for cattle and pigs). The negative control group (NC) was injected with the same volume of PBS. Vaccination was performed twice with an interval of 28 days. 1 mL of vaccine (single dose) was injected via deep intramuscular route in the neck of the animals. Blood samples were collected at 0, 7, 14, 28, 42, 56, 70 and 84 days after vaccination of pigs for serological assays. The experimental results are shown in Figure 8d.

[0099] In Figure 8d, (a) IgG concentration, (b) IgM concentration, (c) IgA concentration are shown. Data represent the mean ± SEM of triplicate determinations (n ​​= 4 or 6 per group). Statistical analysis was performed using two-way ANOVA followed by Tukey's test. *p<0.05; **p<0.01; ***p<0.001; and ****p<0.0001.

[0100] The experimental results showed that O PA2-C3d and A22-C3d effectively induced not only SP-specific antibody titers (via SP ELISA) in MDA(+) / MDA(-) animals, but also SP-nonspecific antibodies, including IgG (an indicator of neutralizing antibodies), IgM (the first natural antibody induced during pathogen infection or vaccination) and IgA (a core element for inducing mucosal immunity) levels. Maternal IgG and IgA can weaken mucosal accessory cell responses in early infancy, and maternal IgG regulatory T cell epitopes induce immune tolerance rather than immunogenicity. Based on the above results, the immune-enhancing recombinant FMD vaccine strains O PA2-C3d and A22-C3d can effectively induce active immunity in the host by overcoming MDA interference-mediated immune resistance in MDA(+) animals, and can also effectively induce active immunity in the host by overcoming MDA interference-mediated immune resistance in MDA(+) animals. When vaccinated in DA(-) animals or animals aged 2-3 months (a period when MDA titers are even lower according to the current vaccine program), strong cellular and humoral immune responses can be induced. These results suggest that the C3d spike (insertion of C3d into the surface of the antigen) on the antigen persistently stimulates the B cell surface receptor to directly activate B cells, and that the highly immunogenic O PA2-C3d and A22-C3d antigens provide a strong T cell-mediated immune response to generate more efficient high titer and neutralizing antibodies (Figure 8d).

[0101] From the above results, O PA2-C3d and A22-C3d are considered to be immune-enhancing FMD vaccine strains with excellent immunogenicity and play an important role in short-term immune induction and early host defense. In addition, the bivalent test vaccine containing O PA2-C3d antigen + A22-C3d antigen is expected to be more effective in overcoming maternal antibody interference by simultaneously inducing strong early cellular and humoral immune responses when vaccinating target animals.

[0102] <Experimental Example 4> Evaluation of the effect of overcoming maternal antibody interference in pigs and simultaneously inducing cellular and humoral immune responses To evaluate the effect of overcoming maternal antibody interference and simultaneously inducing cellular and humoral immune responses in pigs, experiments were performed using MDA(+)- or MDA(-)- pigs (Fig. 6a). In MDA(+)- individuals, O PA2-C3d+A22-C3d showed a strong effect of overcoming maternal antibody interference, especially in the antibody titer by SP O ELISA, and in the antibody titer by SP A ELISA, the antibody titer itself decreased slightly at the beginning of vaccination and tended to increase after boosting. This is because the SP site is different from the antigen coated on the SP A ELISA plate due to the characteristics of the FMDV type A antigen, and it is considered that the detection itself was low and affected the PI (percent inhibition) value. For a more accurate evaluation, it was considered necessary to examine whether it is possible to overcome maternal antibody interference through VN titer.

[0103] In contrast, in MDA(-)- individuals, O PA2-C3d+A22-C3d induced a strong increase in antibody titers as determined by SP O ELISA and SP A ELISA, and its antibody titer-inducing ability was significantly higher than that of O PA2+A22 used as the backbone (Figure 8b).

[0104] In addition, VN titers against O PA2 and A22 were checked to confirm the actual virus neutralization effect. The animals were vaccinated with a vaccine from Company B (the source of the vaccine used is not stated in order to protect the interests of the company and prevent conflicts), so VN titers against O1 Campos, A2001 Argentina, and A24 Cruzeiro were checked using serum at 0 dpv before vaccination to confirm the presence or absence of maternal antibodies. As a result, the VN titers for the MDA(+) and MDA(-) groups were accurately classified as positive and negative, respectively, and these animals were used to vaccinate the respective groups.

[0105] The serum samples collected from 0 to 84 dpv were used to evaluate the VN response to OPA2 and A22. As a result of checking the titers, since the vaccine strain antigen in the vaccine administered to the sows was different from the antigen in the vaccine administered by the present invention, the VN titers against OPA2 and A22 were below the protective level at the initial stage (0 dpv) <1.2 Log regardless of the MDA(+) / MDA(-) group. 10 Furthermore, administration of the O PA2-C3d + A22-C3d bivalent test vaccine resulted in significantly higher VN titers in both maternal transfer antibody positive / negative groups than administration of the O PA2 + A22 bivalent test vaccine (Figure 7).

[0106] Based on the above results, the immune-enhancing FMD vaccine strain developed to overcome maternal antibody interference was It is believed that O PA2-C3d and A22-C3d, which are the antigens that can effectively induce active immunity in the host by overcoming interference phenomena such as immune tolerance even in the presence of maternal antibodies. It is also believed that they can induce a strong humoral immune response when inoculated into target animals (pigs) at 8 to 12 weeks of age, a time when maternal antibodies are decreasing according to currently used vaccine programs. This is believed to be because C3d spiked in the antigen continuously stimulates B cell surface receptors to directly activate B cells, while the highly immunogenic O PA2-C3d and A22-C3d antigens induce a strong T cell-mediated cellular immune response, enabling more efficient production of high titer antibodies and neutralizing antibody titers.

[0107] To prove this, bivalent test vaccine containing O PA2-C3d+A22-C3d antigen was confirmed to be mediated by cellular immune responses in MDA(+) / MDA(-) pigs. The positive control group (PC) received the bivalent test vaccine containing the backbone strain O PA2+A22 antigen, and the negative control group (NC) received PBS. The test vaccine containing O PA2-C3d+A22-C3d antigen was confirmed to increase the expression of type I IFN, which has antiviral effects, to a very high level at the early stage of vaccination (7 dpv) in both MDA(+) / MDA(-) conditions, and was expected to effectively protect the host against FMDV infection at the early stage of vaccination. In the case of IFNγ, a T helper (Th)1 cell-associated cytokine, the expression level was lower than that of IFNα and IFNβ, but it showed significant expression of >2 fold-change or more (p<0.05), and was therefore determined to effectively induce T cell-mediated cellular immune responses. The expression of IL-1β, which is involved in inflammasome activity, Th17 cells, and IL-17A derived from non-conventional T cells (γδT cells) was also very high in the experimental group administered antigens isolated and purified from the vaccine strain with C3d inserted. Previous research has revealed that the expression of IL-23p19 and IL-23R is very important in the host's early defense, and this invention also found that their expression shows a "cytokine storm" level in the early stages and then normalizes.

[0108] Dendritic cells (DCs), macrophages (M Φ When IL-23A is secreted through the stimulation of pathogen recognition receptors (PRRs) in innate immune cells such as T cells, it binds to IL-23R on the surface of innate-like immune cells, non-traditional T cells, stimulating the cells to produce IL-17A. The produced IL-17A plays a crucial role in the host's initial defense by recruiting neutrophils to the pathogen infection site to form NETs (neutrophil extracellular traps) and induce NETosis of the pathogen.

[0109] In addition, the IL-23 / IL-17A axis is known to link innate and adaptive immunity, and it is believed that the test vaccine containing the O PA2-C3d+A22-C3d antigen will simultaneously induce innate and adaptive immune responses through the secretion of such inflammatory cytokines.

[0110] CD4 + Th subsets and CD4 + T regulatory cells (T regs ) differentiation and survival, and is essential for the generation of memory cells, and is involved in the synthesis of IL-2 and T regs In the case of TGFβ, which is known to be involved in the development of inflammatory cells and the induction of immunological tolerance in DCs, the expression was slightly higher in the experimental group, but no significance was observed between the groups. The expression of IL-10, an anti-inflammatory cytokine, was also significantly increased in the experimental group (p<0.05), which is presumed to be due to host homeostasis to regulate the "cytokine storm" of inflammatory cytokines. The expression of IL-4 and IL-6, cytokines derived from Th2 cells, was significantly higher in the MDA(+) group than in the MDA(- ) group, it was determined that the expression levels of these cytokines are increased in the presence of passive immunity due to maternal antibodies.

[0111] CD80 and CD86 costimulatory signaling, which cooperates with T cell receptor (TCR) signals to promote T cell activation, was increased in the OPA2-C3d+A22-C3d administration group, suggesting that these immune-enhancing FMD vaccine strains can effectively present antigens to T cells and stimulate T cells effectively.

[0112] In the case of MHC class I, gene expression was higher in the MDA(+) group than in the MDA(-) group, and was even lower in the vaccinated group than in the NC group. However, gene expression was low in the presence of passive immunity, and therefore cytotoxic CD8 +In contrast, MHC class II was highly expressed in the MDA(-) group compared to the MDA(+) group, and although there was no significant difference between the groups, it tended to increase in the experimental group. This suggests that the antigen of the C3d-inserted immune-enhancing vaccine strain is involved in the recognition of antigens by APCs (DCs, M Φ CD4 induces effector cell cooperation and regulation through MHC class II presentation by CD4+ cells (e.g., CD4+, CD8+, CD9+, B+, etc.) + It has been confirmed that it activates T cells, and it is believed that it can induce sustained cell-cell contact and T cell activation through interaction with the MHC complex.

[0113] On the other hand, expression of CD21, which is a direct receptor for C3d, was significantly increased in both MDA(+) and MDA(-) conditions by vaccination with a test vaccine containing a FMD vaccine strain antigen fused with C3d (p<0.01, p<0.0001), suggesting that B cell activation is possible through stimulation of C3d on the FMDV surface and binding to CD21.

[0114] The expression of CD28 and ICOS, which are costimulatory signals that are costimulated during T cell activation and play an important role in the induction of memory T cells, was significantly increased under the MDA(+) / MDA(-) conditions upon administration of the test vaccine containing OPA2-C3d+A22-C3d antigen (CD28: p<0.0001; p<0.05; ICOS: p<0.01; p<0.00001). In particular, the expression of ICOS induced a significant difference between the experimental group and the PC group (MDA(+): p<0.05; MDA(-): p<0.0001), and the C3d-fused FMD vaccine strain antigen increased the costimulation of T cells and lymphocytes, inducing significant expression of IFNγ. In addition, ICOS is an immunoglobulin domain and is known to affect the intestinal immune relationship for IgA production, and it is expected that it will be possible to use FMD vaccine strains to simultaneously induce systemic and mucosal immunity in the future. Since CTLA4 expression also shows a similar tendency to ICOS expression, it is believed that the CTLA pathway is induced by ICOS expression, and it is speculated that the induced CTLA4 induces the conversion of regulatory T cells to suppress autoimmunity by the expression of inflammatory cytokines at the "cytokine storm" level when FMD vaccine is administered to overcome maternal antibody interference in the cytoplasmic domain.

[0115] Meanwhile, in the present invention, the expression of AHNAK was significantly increased in the OPA2-C3d+A22-C3d group under MDA(-) conditions (p<0.001), and was somewhat higher in the experimental group under MDA(+) conditions, but no significant difference was observed between the groups. AHNAK is a large 700 kDa protein previously identified as a structural scaffold protein, and has been involved in various cellular processes such as cell structure, intracellular trafficking, cell membrane regeneration, regulated extracellular efflux, and calcium signaling pathways during T cell differentiation and T cell activation.

[0116] Cytolytic CD8 +T cells (CTLs) kill virus-infected cells in a calcium-dependent manner. AHNAK is expressed in mature CTLs but not in naïve cells. ve CD8 + It has been reported that ANHAK1 is not expressed in T cells and is essential for proper functioning in the induction of immune responses. - / - ) CTLs have shown a marked decrease in Granzyme B production, cytolytic activity, and IFN-γ secretion after TCR stimulation.

[0117] Therefore, it is believed that the test vaccine containing the OPA2-C3d+A22-C3d antigens can induce T cell activation and CTL responses via the expression of AHNAK.

[0118] In addition, the immune-enhancing FMDV antigen according to the present invention induces IFNγ secretion, which is an indicator of cellular immune response, and to verify the specific cellular immune response induced by the C3d-inserted FMDV antigen, "C3d"-inserted FMDV (O PA2-C3d, A22-C3d) Ag-mediated IFNγ secretion was confirmed by in vitro ELISpot analysis using peritoneal exudate cells (PEC) isolated from mouse peritoneal lavage fluid and peripheral blood mononuclear cells (PBMC) isolated from porcine whole blood.

[0119] As a result, inactivated FMDV antigens derived from O PA2-C3d and A22-C3d induced much higher levels of IFNγ secretion in mouse PECs and pig PBMCs than the control group (Figure 8e). Collectively, these results demonstrated that O PA2-C3d and A22-C3d can induce Th1-type immune responses.

[0120] <Experimental Example 5> Measurement of antigen amount in simple kit and evaluation of differentiation from field strains Inactivated antigens were produced and purified using two recombinant FMD viruses, O PA2-C3d and A22-C3d, produced according to the present invention, and two backbone viruses, O PA2 and A22, which were positive controls (PCs). Using these, we performed antigen quantity measurement using a simple kit and a test to distinguish them from field strains. As a result, even a small amount of 2.34 ng (1 / 640 dose) was confirmed to have an SP-positive band, and since no NSP band was formed, it was found that it was possible to distinguish them from field strains (Figure 9). Electron microscope (TEM) observation of the antigen (146s particle) purified through a sucrose density gradient confirmed that there was no problem with the formation of 146s particles, and we attempted to use this as a FMD test vaccine antigen (Figure 10).

Claims

1. A recombinant plasmid having the sequence of SEQ ID NO:

11.

2. An immune enhancing recombinant foot and mouth disease type A virus produced from the recombinant plasmid of claim 1.

3. An immune-enhancing recombinant foot-and-mouth disease virus type A antigen obtained by purifying and isolating the immune-enhancing recombinant foot-and-mouth disease virus according to claim 2.

4. A foot-and-mouth disease vaccine composition comprising the immuno-enhancing recombinant foot-and-mouth disease virus according to claim 2 or the immuno-enhancing recombinant foot-and-mouth disease virus antigen according to claim 3.

5. A diagnostic kit for foot-and-mouth disease, comprising the immunoenhancing recombinant foot-and-mouth disease virus according to claim 2 or the immunoenhancing recombinant foot-and-mouth disease virus antigen according to claim 3.

6. A method for diagnosing FMD using the FMD diagnostic kit according to claim 5.

7. A method for preventing or treating foot-and-mouth disease using the foot-and-mouth disease vaccine composition according to claim 4.

Citation Information

Patent Citations

  • regulation of the immune response

    JP1998509723A

  • Recombinant virus expressing protective antigen of foot-and-mouth o-panasia-2 genotye, and manufacturing method thereof

    KR1020150014015A

  • Smart fence using millimeter wave sensor

    KR1020220050682A

  • Foot-and-mouth disease recombinant type A virus inserted with T cell epitope and vaccine composition containing inactivated antigen isolated and purified from this virus

    KR102234754B1

  • peptide

    US20140219918A1